Wells Fargo
BOLT icon

Wells Fargo’s Bolt Biotherapeutics BOLT Stock Holding History

Wells Fargo’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$295 – 6946
2024
Q1 		$295 Buy
11
+1
+10% +$23 ﹤0.01% 6405
2023
Q4 		$232 Hold
10
– – ﹤0.01% 6574
2023
Q3 		$205 Buy
10
+2
+25% +$49 ﹤0.01% 6576
2023
Q2 		$202 Hold
8
– – ﹤0.01% 6696
2023
Q1 		$210 Buy
8
+1
+14% +$29 ﹤0.01% 6763
2022
Q4 		$194 Hold
7
– – ﹤0.01% 6628
2022
Q3 		$0 Buy
7
+3
+75% +$124 ﹤0.01% 6679
2022
Q2 		$0 Sell
4
-56
-93% -$2.17K ﹤0.01% 6817
2022
Q1 		$3K Sell
60
-406
-87% -$27.3K ﹤0.01% 6567
2021
Q4 		$45K Buy
466
+463
+15,433% +$87.9K ﹤0.01% 6014
2021
Q3 		$1K Sell
3
-5
-63% -$1.41K ﹤0.01% 6660
2021
Q2 		$2K Sell
8
-190
-96% -$77.1K ﹤0.01% 6527
2021
Q1 		$130K Buy
+198
New +$129K ﹤0.01% 5361

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Wells Fargo's BOLT Position: Q2 2024 in Review

Wells Fargo sold out of Bolt Biotherapeutics (BOLT) in Q2 2024, closing a stake of 11 shares — an estimated $295 sold.

Wells Fargo first reported a position in BOLT in Q1 2021 and held it in 13 quarters. The position peaked at $130K in Q1 2021. 36 funds tracked by Wall St. Rank hold BOLT as of Q2 2024.

  • Wells Fargo reported no remaining Bolt Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 11 Bolt Biotherapeutics shares in Q2 2024, an estimated $295.
  • Wells Fargo first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 13 quarters.
  • Wells Fargo's Bolt Biotherapeutics position peaked at $130K in Q1 2021.
  • 36 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.